Open AccessAntifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
Author(s) -
С. Н. Авдеев,
Natalia V. Trushenko
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-15-131-136
Subject(s) - medicine , idiopathic pulmonary fibrosis , usual interstitial pneumonia , pirfenidone , pulmonary fibrosis , intensive care medicine , pneumonia , pharmacotherapy , fibrosis , lung
Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonia that is characterized by a steadily progressive course and poor prognosis. The worsening pulmonary fibrosis resulting in honeycomb lungs accounts for the deterioration of clinical symptoms and functional status in patients with IPF. Today, the drugs with anti-fibrotic properties are recommend as a drug therapy for IPF. The article provides information on the efficacy and safety of this therapy as well as practical guidelines on the management of patients with IPF receiving such therapy.